Combined HAIC, Lenvatinib and Pucotenlimab As Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 11, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

June 30, 2028

Conditions

Cholangiocarcinoma Non-resectable

Interventions

PROCEDURE

HAIC

administration of gemcitabine and oxaliplatin via the tumor feeding arteries every 3 weeks.

DRUG

Lenvatinib plus pucotenlimab

lenvatinib (8mg, qd) plus pucotenlimab (200mg, q3w)

Trial Locations (1)

RECRUITING

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

All Listed Sponsors

lead

Tongji Hospital

OTHER